A Phase II, Open-Label Study to Assess Safety and Management Change Using 68 Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study (2021)
Attributed to:
Next generation molecular imaging and therapy with radionuclides
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.2967/jnumed.120.257527
PubMed Identifier: 33741648
Publication URI: http://europepmc.org/abstract/MED/33741648
Type: Journal Article/Review
Parent Publication: Journal of Nuclear Medicine
Issue: 12
ISSN: 0161-5505